Nitric Oxide Scavenging by Hydroxocobalamin May Account for Its Hemodynamic Profile

Background. Antidotal doses of hydroxocobalamin are associated with transient increases in blood pressure in some animals and humans. These studies in anesthetized rabbits were undertaken to explore the possible mechanisms underlying the hemodynamic effects of hydroxocobalamin by investigating 1) po...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical toxicology (Philadelphia, Pa.) Pa.), 2006-01, Vol.44 (S1), p.29-36
Hauptverfasser: Gerth, Klaus, Ehring, Thomas, Braendle, Marian, Schelling, Pierre
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 36
container_issue S1
container_start_page 29
container_title Clinical toxicology (Philadelphia, Pa.)
container_volume 44
creator Gerth, Klaus
Ehring, Thomas
Braendle, Marian
Schelling, Pierre
description Background. Antidotal doses of hydroxocobalamin are associated with transient increases in blood pressure in some animals and humans. These studies in anesthetized rabbits were undertaken to explore the possible mechanisms underlying the hemodynamic effects of hydroxocobalamin by investigating 1) possible hemodynamic effects of cyanocobalamin, which is formed on a molar-to-molar basis when hydroxocobalamin binds cyanide, and 2) the interference of hydroxocobalamin with the endothelial nitric oxide system. Methods. Study 1 investigated the hemodynamic effects of cyanocobalamin. This study included two treatment arms: 1) cyanocobalamin (75 mg/kg, IV) followed by saline (n = 7) and 2) saline followed by cyanocobalamin (n = 7). Study 2 assessed the hemodynamic effects of hydroxocobalamin (75 mg/kg, IV) in the presence and absence of the nitric oxide synthase inhibitor L-N -nitro-L-arginine methyl ester (L-NAME; 30 mg/kg, IV). Nitric oxide synthase inhibition itself increases blood pressure. Thus, as part of Study 2, the hemodynamic effects of hydroxocobalamin were also investigated in the presence of an equipressor dose of angiotensin II (ANGII; 0.05 μg/kg/min, IV) in order to determine whether elevated blood pressure per se could interfere with hydroxocobalamin's hemodynamic effects. This study included six treatment arms (designated as first treatment + second treatment): saline + saline (n = 5), L-NAME + saline (n = 7), saline + hydroxocobalamin (n = 7), L-NAME + hydroxocobalamin (n = 7), ANGII + hydroxocobalamin (n = 7), and ANGII + saline (n = 7). Results. In Study 1, the effects of cyanocobalamin on hemodynamic parameters were indistinguishable from those of saline. In Study 2, hydroxocobalamin infusion was associated with moderate hemodynamic effects, including an increase in systemic vascular resistance, an increase in blood pressure, and a decrease in cardiac output. Administration of L-NAME abolished the effects of hydroxocobalamin on all hemodynamic parameters. ANGII at a dose producing a pressor response comparable to that of L-NAME did not influence the hydroxocobalamin-associated hemodynamic changes. Conclusion. These studies in anesthetized rabbits demonstrate that the moderate pressor effect of hydroxocobalamin is not related to the formation of cyanocobalamin but is very likely related to the scavenging of nitric oxide by hydroxocobalamin.
doi_str_mv 10.1080/15563650600811805
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16990191</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68878860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c501t-39bb61480a1cf8c8d416fa76d51ba12854c1e2e2aaeac278b5918c4fc4d1507a3</originalsourceid><addsrcrecordid>eNqFkMFO3TAQRa0KVF5pP6Cbyit2aWeS2HFUNggVHhKUSrRra-I4YJTYYCeU_D2p3pMqhASrWdxzr0aHsc8IXxEUfEMhZCEFSACFqEC8YyuEuspqVYkdtoKqwKxQCHvsQ0q3AFAUQr5neyjrGrDGFbv66cboDL98dK3lV4YerL92_po3M1_PbQyPwYSGehqc5xc08yNjwuRH3oXIz8bE13YI7eyX3PBfMXSutx_Zbkd9sp-2d5_9Ofnx-3idnV-enh0fnWdGAI5ZUTeNxFIBoemUUW2JsqNKtgIbwlyJ0qDNbU5kyeSVakSNypSdKVsUUFGxzw42u3cx3E82jXpwydi-J2_DlLRUqlJKwpsg1iJfTOIC4gY0MaQUbafvohsozhpB_1OuXyhfOl-241Mz2PZ_Y-t4AQ43gPOLtIH-hti3eqS5D7GL5I1Lunht__uz-o2lfrwxFK2-DVP0i-FXvnsCfC6g0A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19525631</pqid></control><display><type>article</type><title>Nitric Oxide Scavenging by Hydroxocobalamin May Account for Its Hemodynamic Profile</title><source>MEDLINE</source><source>Taylor &amp; Francis Medical Library - CRKN</source><source>Taylor &amp; Francis Journals Complete</source><creator>Gerth, Klaus ; Ehring, Thomas ; Braendle, Marian ; Schelling, Pierre</creator><creatorcontrib>Gerth, Klaus ; Ehring, Thomas ; Braendle, Marian ; Schelling, Pierre</creatorcontrib><description>Background. Antidotal doses of hydroxocobalamin are associated with transient increases in blood pressure in some animals and humans. These studies in anesthetized rabbits were undertaken to explore the possible mechanisms underlying the hemodynamic effects of hydroxocobalamin by investigating 1) possible hemodynamic effects of cyanocobalamin, which is formed on a molar-to-molar basis when hydroxocobalamin binds cyanide, and 2) the interference of hydroxocobalamin with the endothelial nitric oxide system. Methods. Study 1 investigated the hemodynamic effects of cyanocobalamin. This study included two treatment arms: 1) cyanocobalamin (75 mg/kg, IV) followed by saline (n = 7) and 2) saline followed by cyanocobalamin (n = 7). Study 2 assessed the hemodynamic effects of hydroxocobalamin (75 mg/kg, IV) in the presence and absence of the nitric oxide synthase inhibitor L-N -nitro-L-arginine methyl ester (L-NAME; 30 mg/kg, IV). Nitric oxide synthase inhibition itself increases blood pressure. Thus, as part of Study 2, the hemodynamic effects of hydroxocobalamin were also investigated in the presence of an equipressor dose of angiotensin II (ANGII; 0.05 μg/kg/min, IV) in order to determine whether elevated blood pressure per se could interfere with hydroxocobalamin's hemodynamic effects. This study included six treatment arms (designated as first treatment + second treatment): saline + saline (n = 5), L-NAME + saline (n = 7), saline + hydroxocobalamin (n = 7), L-NAME + hydroxocobalamin (n = 7), ANGII + hydroxocobalamin (n = 7), and ANGII + saline (n = 7). Results. In Study 1, the effects of cyanocobalamin on hemodynamic parameters were indistinguishable from those of saline. In Study 2, hydroxocobalamin infusion was associated with moderate hemodynamic effects, including an increase in systemic vascular resistance, an increase in blood pressure, and a decrease in cardiac output. Administration of L-NAME abolished the effects of hydroxocobalamin on all hemodynamic parameters. ANGII at a dose producing a pressor response comparable to that of L-NAME did not influence the hydroxocobalamin-associated hemodynamic changes. Conclusion. These studies in anesthetized rabbits demonstrate that the moderate pressor effect of hydroxocobalamin is not related to the formation of cyanocobalamin but is very likely related to the scavenging of nitric oxide by hydroxocobalamin.</description><identifier>ISSN: 0731-3810</identifier><identifier>ISSN: 1556-3650</identifier><identifier>EISSN: 1097-9875</identifier><identifier>EISSN: 1556-9519</identifier><identifier>DOI: 10.1080/15563650600811805</identifier><identifier>PMID: 16990191</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Animals ; Antidotes - pharmacology ; Blood Pressure ; Cardiac Output ; Cyanide ; Cyanide poisoning ; Cyanocobalamin ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - enzymology ; Enzyme Inhibitors - pharmacology ; Free Radical Scavengers - pharmacology ; Hemodynamics - drug effects ; Hydroxocobalamin ; Hydroxocobalamin - pharmacology ; Male ; NG-Nitroarginine Methyl Ester - pharmacology ; Nitric oxide ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - antagonists &amp; inhibitors ; Nitric Oxide Synthase - metabolism ; Rabbits ; Vascular Resistance</subject><ispartof>Clinical toxicology (Philadelphia, Pa.), 2006-01, Vol.44 (S1), p.29-36</ispartof><rights>2006 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c501t-39bb61480a1cf8c8d416fa76d51ba12854c1e2e2aaeac278b5918c4fc4d1507a3</citedby><cites>FETCH-LOGICAL-c501t-39bb61480a1cf8c8d416fa76d51ba12854c1e2e2aaeac278b5918c4fc4d1507a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/15563650600811805$$EPDF$$P50$$Ginformaworld$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/15563650600811805$$EHTML$$P50$$Ginformaworld$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16990191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gerth, Klaus</creatorcontrib><creatorcontrib>Ehring, Thomas</creatorcontrib><creatorcontrib>Braendle, Marian</creatorcontrib><creatorcontrib>Schelling, Pierre</creatorcontrib><title>Nitric Oxide Scavenging by Hydroxocobalamin May Account for Its Hemodynamic Profile</title><title>Clinical toxicology (Philadelphia, Pa.)</title><addtitle>Clin Toxicol (Phila)</addtitle><description>Background. Antidotal doses of hydroxocobalamin are associated with transient increases in blood pressure in some animals and humans. These studies in anesthetized rabbits were undertaken to explore the possible mechanisms underlying the hemodynamic effects of hydroxocobalamin by investigating 1) possible hemodynamic effects of cyanocobalamin, which is formed on a molar-to-molar basis when hydroxocobalamin binds cyanide, and 2) the interference of hydroxocobalamin with the endothelial nitric oxide system. Methods. Study 1 investigated the hemodynamic effects of cyanocobalamin. This study included two treatment arms: 1) cyanocobalamin (75 mg/kg, IV) followed by saline (n = 7) and 2) saline followed by cyanocobalamin (n = 7). Study 2 assessed the hemodynamic effects of hydroxocobalamin (75 mg/kg, IV) in the presence and absence of the nitric oxide synthase inhibitor L-N -nitro-L-arginine methyl ester (L-NAME; 30 mg/kg, IV). Nitric oxide synthase inhibition itself increases blood pressure. Thus, as part of Study 2, the hemodynamic effects of hydroxocobalamin were also investigated in the presence of an equipressor dose of angiotensin II (ANGII; 0.05 μg/kg/min, IV) in order to determine whether elevated blood pressure per se could interfere with hydroxocobalamin's hemodynamic effects. This study included six treatment arms (designated as first treatment + second treatment): saline + saline (n = 5), L-NAME + saline (n = 7), saline + hydroxocobalamin (n = 7), L-NAME + hydroxocobalamin (n = 7), ANGII + hydroxocobalamin (n = 7), and ANGII + saline (n = 7). Results. In Study 1, the effects of cyanocobalamin on hemodynamic parameters were indistinguishable from those of saline. In Study 2, hydroxocobalamin infusion was associated with moderate hemodynamic effects, including an increase in systemic vascular resistance, an increase in blood pressure, and a decrease in cardiac output. Administration of L-NAME abolished the effects of hydroxocobalamin on all hemodynamic parameters. ANGII at a dose producing a pressor response comparable to that of L-NAME did not influence the hydroxocobalamin-associated hemodynamic changes. Conclusion. These studies in anesthetized rabbits demonstrate that the moderate pressor effect of hydroxocobalamin is not related to the formation of cyanocobalamin but is very likely related to the scavenging of nitric oxide by hydroxocobalamin.</description><subject>Animals</subject><subject>Antidotes - pharmacology</subject><subject>Blood Pressure</subject><subject>Cardiac Output</subject><subject>Cyanide</subject><subject>Cyanide poisoning</subject><subject>Cyanocobalamin</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - enzymology</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Free Radical Scavengers - pharmacology</subject><subject>Hemodynamics - drug effects</subject><subject>Hydroxocobalamin</subject><subject>Hydroxocobalamin - pharmacology</subject><subject>Male</subject><subject>NG-Nitroarginine Methyl Ester - pharmacology</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - antagonists &amp; inhibitors</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Rabbits</subject><subject>Vascular Resistance</subject><issn>0731-3810</issn><issn>1556-3650</issn><issn>1097-9875</issn><issn>1556-9519</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFO3TAQRa0KVF5pP6Cbyit2aWeS2HFUNggVHhKUSrRra-I4YJTYYCeU_D2p3pMqhASrWdxzr0aHsc8IXxEUfEMhZCEFSACFqEC8YyuEuspqVYkdtoKqwKxQCHvsQ0q3AFAUQr5neyjrGrDGFbv66cboDL98dK3lV4YerL92_po3M1_PbQyPwYSGehqc5xc08yNjwuRH3oXIz8bE13YI7eyX3PBfMXSutx_Zbkd9sp-2d5_9Ofnx-3idnV-enh0fnWdGAI5ZUTeNxFIBoemUUW2JsqNKtgIbwlyJ0qDNbU5kyeSVakSNypSdKVsUUFGxzw42u3cx3E82jXpwydi-J2_DlLRUqlJKwpsg1iJfTOIC4gY0MaQUbafvohsozhpB_1OuXyhfOl-241Mz2PZ_Y-t4AQ43gPOLtIH-hti3eqS5D7GL5I1Lunht__uz-o2lfrwxFK2-DVP0i-FXvnsCfC6g0A</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Gerth, Klaus</creator><creator>Ehring, Thomas</creator><creator>Braendle, Marian</creator><creator>Schelling, Pierre</creator><general>Informa UK Ltd</general><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>Nitric Oxide Scavenging by Hydroxocobalamin May Account for Its Hemodynamic Profile</title><author>Gerth, Klaus ; Ehring, Thomas ; Braendle, Marian ; Schelling, Pierre</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c501t-39bb61480a1cf8c8d416fa76d51ba12854c1e2e2aaeac278b5918c4fc4d1507a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antidotes - pharmacology</topic><topic>Blood Pressure</topic><topic>Cardiac Output</topic><topic>Cyanide</topic><topic>Cyanide poisoning</topic><topic>Cyanocobalamin</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - enzymology</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Free Radical Scavengers - pharmacology</topic><topic>Hemodynamics - drug effects</topic><topic>Hydroxocobalamin</topic><topic>Hydroxocobalamin - pharmacology</topic><topic>Male</topic><topic>NG-Nitroarginine Methyl Ester - pharmacology</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - antagonists &amp; inhibitors</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Rabbits</topic><topic>Vascular Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gerth, Klaus</creatorcontrib><creatorcontrib>Ehring, Thomas</creatorcontrib><creatorcontrib>Braendle, Marian</creatorcontrib><creatorcontrib>Schelling, Pierre</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical toxicology (Philadelphia, Pa.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gerth, Klaus</au><au>Ehring, Thomas</au><au>Braendle, Marian</au><au>Schelling, Pierre</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nitric Oxide Scavenging by Hydroxocobalamin May Account for Its Hemodynamic Profile</atitle><jtitle>Clinical toxicology (Philadelphia, Pa.)</jtitle><addtitle>Clin Toxicol (Phila)</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>44</volume><issue>S1</issue><spage>29</spage><epage>36</epage><pages>29-36</pages><issn>0731-3810</issn><issn>1556-3650</issn><eissn>1097-9875</eissn><eissn>1556-9519</eissn><abstract>Background. Antidotal doses of hydroxocobalamin are associated with transient increases in blood pressure in some animals and humans. These studies in anesthetized rabbits were undertaken to explore the possible mechanisms underlying the hemodynamic effects of hydroxocobalamin by investigating 1) possible hemodynamic effects of cyanocobalamin, which is formed on a molar-to-molar basis when hydroxocobalamin binds cyanide, and 2) the interference of hydroxocobalamin with the endothelial nitric oxide system. Methods. Study 1 investigated the hemodynamic effects of cyanocobalamin. This study included two treatment arms: 1) cyanocobalamin (75 mg/kg, IV) followed by saline (n = 7) and 2) saline followed by cyanocobalamin (n = 7). Study 2 assessed the hemodynamic effects of hydroxocobalamin (75 mg/kg, IV) in the presence and absence of the nitric oxide synthase inhibitor L-N -nitro-L-arginine methyl ester (L-NAME; 30 mg/kg, IV). Nitric oxide synthase inhibition itself increases blood pressure. Thus, as part of Study 2, the hemodynamic effects of hydroxocobalamin were also investigated in the presence of an equipressor dose of angiotensin II (ANGII; 0.05 μg/kg/min, IV) in order to determine whether elevated blood pressure per se could interfere with hydroxocobalamin's hemodynamic effects. This study included six treatment arms (designated as first treatment + second treatment): saline + saline (n = 5), L-NAME + saline (n = 7), saline + hydroxocobalamin (n = 7), L-NAME + hydroxocobalamin (n = 7), ANGII + hydroxocobalamin (n = 7), and ANGII + saline (n = 7). Results. In Study 1, the effects of cyanocobalamin on hemodynamic parameters were indistinguishable from those of saline. In Study 2, hydroxocobalamin infusion was associated with moderate hemodynamic effects, including an increase in systemic vascular resistance, an increase in blood pressure, and a decrease in cardiac output. Administration of L-NAME abolished the effects of hydroxocobalamin on all hemodynamic parameters. ANGII at a dose producing a pressor response comparable to that of L-NAME did not influence the hydroxocobalamin-associated hemodynamic changes. Conclusion. These studies in anesthetized rabbits demonstrate that the moderate pressor effect of hydroxocobalamin is not related to the formation of cyanocobalamin but is very likely related to the scavenging of nitric oxide by hydroxocobalamin.</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>16990191</pmid><doi>10.1080/15563650600811805</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0731-3810
ispartof Clinical toxicology (Philadelphia, Pa.), 2006-01, Vol.44 (S1), p.29-36
issn 0731-3810
1556-3650
1097-9875
1556-9519
language eng
recordid cdi_pubmed_primary_16990191
source MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete
subjects Animals
Antidotes - pharmacology
Blood Pressure
Cardiac Output
Cyanide
Cyanide poisoning
Cyanocobalamin
Endothelium, Vascular - drug effects
Endothelium, Vascular - enzymology
Enzyme Inhibitors - pharmacology
Free Radical Scavengers - pharmacology
Hemodynamics - drug effects
Hydroxocobalamin
Hydroxocobalamin - pharmacology
Male
NG-Nitroarginine Methyl Ester - pharmacology
Nitric oxide
Nitric Oxide - metabolism
Nitric Oxide Synthase - antagonists & inhibitors
Nitric Oxide Synthase - metabolism
Rabbits
Vascular Resistance
title Nitric Oxide Scavenging by Hydroxocobalamin May Account for Its Hemodynamic Profile
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T15%3A15%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nitric%20Oxide%20Scavenging%20by%20Hydroxocobalamin%20May%20Account%20for%20Its%20Hemodynamic%20Profile&rft.jtitle=Clinical%20toxicology%20(Philadelphia,%20Pa.)&rft.au=Gerth,%20Klaus&rft.date=2006-01-01&rft.volume=44&rft.issue=S1&rft.spage=29&rft.epage=36&rft.pages=29-36&rft.issn=0731-3810&rft.eissn=1097-9875&rft_id=info:doi/10.1080/15563650600811805&rft_dat=%3Cproquest_pubme%3E68878860%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19525631&rft_id=info:pmid/16990191&rfr_iscdi=true